Northern Trust Corp Acquires 10,846 Shares of Annovis Bio, Inc. (NYSE:ANVS)

Northern Trust Corp increased its holdings in Annovis Bio, Inc. (NYSE:ANVS) by 49.4% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 32,780 shares of the company’s stock after buying an additional 10,846 shares during the period. Northern Trust Corp owned about 0.23% of Annovis Bio worth $165,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors also recently bought and sold shares of the company. JPMorgan Chase & Co. bought a new position in Annovis Bio in the third quarter worth approximately $31,000. XTX Topco Ltd acquired a new position in shares of Annovis Bio during the fourth quarter worth $59,000. Atria Wealth Solutions Inc. acquired a new position in shares of Annovis Bio during the fourth quarter worth $65,000. Lokken Investment Group LLC increased its position in shares of Annovis Bio by 49.0% during the fourth quarter. Lokken Investment Group LLC now owns 18,235 shares of the company’s stock worth $92,000 after purchasing an additional 6,000 shares in the last quarter. Finally, Greenwich Wealth Management LLC increased its position in shares of Annovis Bio by 93.9% during the fourth quarter. Greenwich Wealth Management LLC now owns 31,951 shares of the company’s stock worth $161,000 after purchasing an additional 15,476 shares in the last quarter. Institutional investors own 15.83% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts have recently issued reports on ANVS shares. Canaccord Genuity Group reduced their price target on Annovis Bio from $26.00 to $17.00 and set a “buy” rating on the stock in a research report on Thursday, May 15th. D. Boral Capital reaffirmed a “hold” rating on shares of Annovis Bio in a research report on Monday, February 10th. One research analyst has rated the stock with a hold rating, four have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, Annovis Bio presently has a consensus rating of “Buy” and a consensus target price of $34.75.

Annovis Bio Price Performance

Shares of ANVS opened at $2.61 on Wednesday. The firm has a market capitalization of $50.78 million, a PE ratio of -0.58 and a beta of 1.46. Annovis Bio, Inc. has a 1-year low of $1.11 and a 1-year high of $17.88. The company’s fifty day moving average price is $1.64 and its 200-day moving average price is $3.23.

Annovis Bio (NYSE:ANVS) last announced its quarterly earnings data on Tuesday, May 13th. The company reported ($0.32) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.47) by $0.15. As a group, research analysts anticipate that Annovis Bio, Inc. will post -2.19 EPS for the current fiscal year.

About Annovis Bio

Annovis Bio, Inc, a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead product candidate is Buntanetap, which has completed three Phase 1/2 clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, and other chronic neurodegenerative diseases.